***TERRESTRIAL MANUAL* REVISION: ADVICE FOR MEMBER COUNTRY COMMENTS**

Chapter Number and Title: Chapter 3.8.11 Scrapie

Country making the comments:

Date:

It would be appreciated if the following guidance is followed when making a reply:

1. Comments may be general or specific, but specific comments are more valuable. General comments should be such that some conclusion and action can be taken in response to them. For example, instead of stating “This test is no longer used in our laboratory”, indicate the reasons the test is no longer used and what test is used instead.

2. Specific comments should be identified by indicating the line number in the text, to facilitate the editorial process.

3. Highlighting typing or technical errors is welcome, but the correct word or figure should be indicated in its place. For example, instead of indicating simply “0.8 M is too high”, the preferred value should also be indicated.

4. Bear in mind that the introductory chapters (Part 1 of the *Terrestrial Manual*) set general standards for the management of veterinary diagnostic laboratories and vaccine facilities and are not intended to be exhaustive, and indeed none of the chapters can give a completely comprehensive cover of the subject, otherwise the *Terrestrial Manual* would be too long. However, assistance in indicating priorities is always helpful.

5. The *Terrestrial Manual* is intended for world-wide use. The chapters need to reflect the development of new technology, while maintaining the established methods, usually requiring less sophisticated apparatus. New technology should not be described in detail until it has gained wide acceptance as a reliable method.

6. We recommend that if you have no specific comments, please respond to the OIE to that effect.

7. Any comments, proposed changes or revisions should be supported by clear evidence (the scientific rationale) such that some conclusion and action can be taken in response to them.

*Your participation in the OIE Standard-setting process is valued. Thank you for your engagement in the process!*

*General Comments*

*Specific Comments* (*add continuation sheets if required*)

*line:*

Chapter 3.8.11.

scrapie

SUMMARY

**Description of the disease:** ~~Scrapie is a~~ The term scrapie encompasses two different pathological entities: classical and atypical scrapie. Both conditions are chronic, neurodegenerative, fatal [disease](http://www.oie.int/index.php?id=169&L=0&htmfile=glossaire.htm#terme_maladie)sof sheep and goats~~. So-called ‘atypical’ scrapie is clinically, pathologically, biochemically and epidemiologically unrelated to ‘classical’ scrapie, is likely to be non-contagious and a spontaneous degenerative condition of older sheep and rarely of goats~~ and are caused by similar agents. However, they differ in clinical presentation, pathogenesis, pathology, biochemical properties and epidemiology. This chapter describes tests for both conditions so that they may be differentiated.

Classical scrapie is characterised by vacuolar changes in the central nervous system (CNS). It has been recognised as a clinical disorder for more than 250 years, and is classified as a transmissible spongiform encephalopathy (TSE), or prion disease, as defined by the accumulation of an abnormal form of a host cell membrane-bound glycoprotein (prion protein or PrP) referred to as PrPSc, in the CNS. ~~In animals of some genotypes, PrP~~~~Sc~~ ~~accumulation is also detectable in lymphoreticular tissues.~~ Polymorphisms of the PrP gene are associated with susceptibility to scrapie. Breeding for resistance has been used as an effective tool in the control of ovine classical scrapie.~~, but no~~ Depending on PrP genotype, ~~appears to~~ PrPSc can also be ~~completely resistant to infection~~ detected in lymphoreticular tissues of classical scrapie cases.

The more recently identified condition known as atypical scrapie has some clinical and pathological features similar to classical scrapie but is not considered to be transmitted in field situations. The epidemiology is consistent with a non-contagious condition that occurs sporadically. Consequently, surveillance for classical scrapie will detect occasional cases of atypical scrapie. In sheep, it has also been reported in ~~sheep~~ animals with PrP genotypes that are relatively resistant to classical scrapie.

Classical scrapie is endemic in many countries, where it has often been introduced by importation. ~~Australia and New Zealand have maintained freedom from classical scrapie through strict restrictions on imports and other measures.~~ For up-to-date information on the occurrence of scrapie, consult the OIE WAHIS interface[[1]](#footnote-2). Classical scrapie may be transmitted from dam to offspring in the period from parturition to weaning, and ~~potentially~~ in utero. It can also be transmitted horizontally to unrelated sheep or goats. The infectious material can persist for several years on pastures and in buildings. Fetal membranes are a source of infection, and milk from clinically affected animals can transmit disease. The incubation time between primary infection and clinical disease is usually longer than 1 year and may sometimes exceed the commercial lifespan of the animal. The majority of cases occur between 2 and 5 years of age. Clinical disease develops only if the agent enters the CNS. Atypical scrapie, where it presents clinically, is reported mostly in older animals, and occurs with a geographical distribution suggestive of a spontaneous disease, although it has been transmitted experimentally.

**Detection of the agent:** ~~The classical disease~~ Classical scrapie may be recognised by clinical signs, which are variable but usually start insidiously with behavioural abnormalities that progress to more obvious neurological signs, including pruritus and incoordination. Affected animals have poor body condition. Atypical scrapie cases may present with ataxia. Diagnosis is confirmed by demonstration of vacuolation or the immuno-detection of PrPSc in target areas within the brain. Immuno-detection of PrPSc in brain samples forms the basis of the rapid tests, which are most often used in active surveillance programmes. In experimental studies in sheep and goats, PrPSc accumulation in the brain is not detectable until several months after challenge, so a negative test result does not necessarily equate to an uninfected animal.

Detection of PrPSc in lymphoreticular tissues during the incubation period of classical scrapie in some animals offers a means of preclinical diagnosis of infection and may be useful for surveillance purposes. ~~It~~ Testing can also be performed in live animals using biopsied tissue. It is not, however, appropriate for detection of atypical scrapie, or a proportion of classical scrapie cases, so it can be used only to confirm the presence of infection and cannot be used to prove its absence.

Currently recognised forms of scrapie can be transmitted with variable efficiency to a range of wild type and PrP transgenic laboratory rodents by inoculating them with infected brain tissue, but long incubation times preclude this as a practical diagnostic procedure.

**Serological tests:** Scrapie infection is not known to elicit any specific immune response and so there are no diagnostic tests to detect specific antibodies.

**Requirements for vaccines ~~and diagnostic biologicals~~:** There are no ~~biological products~~ vaccines available.

A. introduction

Classical scrapie (also known as la tremblante; Traberkrankheit; Gnubberkrankheit; Prúrigo lumbar) is a naturally occurring progressive, fatal, infectious, neurodegenerative disease of sheep and goats that has been recognised ~~for at least 250 years~~ since the eighteenth century, and has been reported in Europe, North America, Asia and Africa. There is no evidence of a causal link between classical or atypical scrapie and human TSEs. It is the archetype of the transmissible spongiform encephalopathies (TSEs). Prion disorders with similar pathology have been found to occur naturally in several species including man (Hornlimann, 2006). They are defined by the consistent accumulation of an abnormal isoform (PrPSc) of the host-encoded protein (PrPC) in the central nervous system (CNS), and variable PrPSc detection in other tissues such as in the lymphoreticular system (LRS) and other tissues/body fluids.

Atypical scrapie (also known as Nor98), is also a neurodegenerative disease of sheep and goats first described in Norway in 1998 (Benestad *et al*., 2008). Like the classical disease it is associated with abnormal prion protein accumulations, however unlike classical scrapie it has not been shown to be naturally transmitted ~~to in contact animals~~ under field conditions. Active surveillance using rapid immunochemical methods has provided evidence for its widespread occurrence throughout Europe, with reports of cases also in the Falkland Islands (Epstein *et al*., 2005), North America (Loiacono *et al*., 2009), Australia and New Zealand (Kittelberger *et al.,* 2010). Although the epidemiology is not suggestive of transmission in the field (Benestad *et al*., 2008) and it is not considered transmissible from an animal health perspective, it can be transmitted experimentally (Simmons *et al.,* 2011). Retrospective studies have identified cases from the 1980s, predating active surveillance. Atypical scrapie has been identified in sheep of genotypes considered to be relatively resistant to classical scrapie, and in goats. Co-infection of classical and atypical scrapie is a very rare occurrence with a single case having been reported worldwide (Mazza *et al.*, 2010).

Various disease-specific isoforms of the abnormal prion protein (PrPSc) are now widely regarded to be the causal agents in prion diseases. Disease characterisation is based on a range of host phenotypic parameters, such as clinical signs, histopathological profile and immunopathology, PrPSc biochemical characteristics such as protease sensitivity and cleavage site and, if necessary, biological parameters in rodent models.

1. Clinical signs

The clinical signs of classical scrapie (Konold & Phelan, 2014) usually start insidiously, often with behavioural changes that are evident only from repeated inspections. These subtle presenting features, which may include apparent confusion, separation from the flock and a staring gaze, progress to a more definite neurological illness, frequently characterised by signs of pruritus and ataxia or incoordination of gait. Either the pruritus or the ataxia usually emerges to dominate the clinical course. Death may occur after a protracted period of only vague neurological signs or may even occur without premonitory signs. These clinical signs, individually, are not disease-specific and clinical suspicion of disease should be confirmed by further testing.

Pruritus is recognised principally by compulsive rubbing or scraping against fixed objects, nibbling at the skin and scratching with a hind foot or horns. This results in extensive loss of wool, particularly over the lateral thorax, flanks, hindquarters and tail head. The persistence of pruritus often results in localised self-inflicted skin lesions. These may occur in areas of wool loss and on the poll, face, ears and limbs. A characteristic ‘nibble reflex’ can often be elicited by scratching the back, and may also be evoked by the sheep’s own scraping movements. Some sheep or goats with scrapie, however, may not present with evident signs of pruritus. Ataxia or incoordination of gait may first become apparent as difficulty in positioning the hind limbs on turning, swaying of the hindquarters and a high stepping or trotting gait of the forelimbs. Stumbling and falling occur, but the animal is generally able to quickly regain a standing posture. These signs progress to weakness and recumbency. Other signs of classical scrapie may include teeth grinding (bruxism), low head carriage, a fine head or body tremor and, rarely, seizures or visual impairment. In most cases, there is also a loss of bodily condition or weight.

In atypical scrapie the clinical features are dominated by ataxia in the absence of pruritus; circling has also been observed.

Video-clips illustrating the clinical signs of scrapie can be viewed on the webpages of ~~TSE European Union Reference Laboratory, TSE-LAB-NET (~~[~~http://www.tse-lab-net.eu/~~](http://www.tse-lab-net.eu/)~~)~~ the [OIE Reference Laboratory](https://science.vla.gov.uk/tseglobalnet/) in the UK[[2]](#footnote-3).

Progression of the clinical disease is very variable, lasting for a week or up to several months, with an inevitably fatal outcome. There is also variation in the clinical signs among individual animals and in different breeds of sheep. These variations may be due to the influence of host genotype and strain of agent. Environmental factors may also have an influence on the disease course. The clinical diagnosis of individual cases of classical scrapie can therefore be difficult. The clinical signs may, especially in the early phase of the disease, resemble those of some other conditions of adult small ruminants, including ectoparasitism, Aujeszky’s disease (pseudorabies), rabies, cerebral listeriosis, maedi-visna (ovine progressive pneumonia), pregnancy toxaemia (ketosis), hypomagnesaemia and chemical and plant intoxications.

2. Host genetic factors

Agent strain and host variables determine the expression of disease. In sheep, different PrP genotypes are associated with relative susceptibility to TSEs. Polymorphisms at codons 136 and 171 are of particular significance in determining overall susceptibility of sheep to classical scrapie, while variations at 141 and 154 affect susceptibility of sheep to atypical scrapie. ~~In goats, PrP genotype also influences susceptibility to disease.~~

In goats, PrP genotype also influences susceptibility to disease. However, in this species the PrP sequence is more variable compared with sheep, and polymorphisms may have diverse distribution in goat populations depending on breed and geographical location. Therefore, genetic programmes aiming at increasing resistance to classical scrapie in one region may not be universally applicable. Polymorphisms at codons 146 and 222 affect susceptibility to classical scrapie and can be used to increase genetic resistance in goat herds. Very little is known about the influence of genetics on atypical scrapie in goats (See EFSA [2017] for recent overview).

The mechanisms by which strain and host parameters influence disease phenotype are still incompletely understood. (See EFSA [2014] for recent overview.)

3. Strain characterisation

Strain characterisation historically relied upon rodent bioassay. The ability to distinguish classical scrapie from bovine spongiform encephalopathy (BSE) is of particular importance in small ruminants because of BSE’s zoonotic nature and the potential for past exposure of small ruminants through contaminated feed. For this purpose, molecular typing uses differential epitope binding of PrPSc in immunohistochemistry (IHC) or Western immunoblot~~ting~~. However, if BSE cannot be discriminated from classical scrapie unequivocally by molecular typing, rodent bioassays must be initiated to resolve the issue.

4. Surveillance

Because of the known inadequacies of baseline (passive) surveillance and the absence of active surveillance components, the classical scrapie status of many countries is unknown. Objectively establishing freedom from infection in a national flock requires sustained and substantial levels of active surveillance. Some countries have never recorded classical scrapie against a background of general and/or targeted surveillance, while others have maintained freedom for various periods through rigorous preventative policies and monitoring. Classical scrapie usually occurs in sheep 2–5 years of age. Rarely are cases present in sheep less than 1 year old. In atypical scrapie a significant proportion of cases have been reported in sheep over 5 years of age. Rarely, sheep have been identified with mixed infections of classical and atypical scrapie. In some instances with classical scrapie, the commercial lifespan of the sheep may be too short or exposure has occurred too late in life for the clinical disease to develop. Classical and atypical scrapie have also been described in goats, and classical scrapie in captive moufflon (*Ovis musimon*). Most breeds of sheep are affected. Classical scrapie may be transmitted from dam to offspring in the period from parturition to weaning, and ~~potentially~~ *in utero* (Spiropoulos *et al.,* 2014). Infection can also pass horizontally to unrelated animals, even without direct contact (Dexter *et al.,* 2009). Fetal membranes are known to be a source of infection, and milk can also transmit disease (Konold *et al*., 2013). Pasture previously grazed by, or buildings previously inhabited by, infected animals also represent a risk (Gough *et al.,* 2015; Hawkins *et al.,* 2015). Animals incubating the disease, and even animals that never develop clinical signs, may still be a source of infection to others.

5. Biosafety

The biohazard for humans from scrapie diagnostic testing appears to be limited, but laboratory manipulations with potentially contaminated material must be performed at an appropriate biosafety and containment level determined by biorisk analysis (see Chapter1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*). Although Creutzfeldt-Jakob disease (CJD) of humans has been found to occur at no greater frequency in those with occupations providing closest contact with the scrapie agent, the extreme chemical and physical resistance of the scrapie agent and the fact that it is experimentally transmissible by injection to a wide spectrum of mammalian species, including humanised transgenic mice (Cassard *et al.,* 2014) and non-human primates (Comoy *et al.,* 2015) suggests the prudence of preventing human exposure.

b. DIAGNOSTIC TECHNIQUES

Table 1. Test methods available for diagnosis of scrapie and their purpose

| Method | **Purpose** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| Population freedom from infection | Individual animal freedom from infection prior to movement | Contribute to eradication policies | Confirmation of clinical cases | Prevalence of infection – surveillance | Immune status in individual animals or populations post-vaccination |
| **Detection of the agent** | | | | | | |
| **Histopathology** | – | – | – | + | – | – |
| **IHC** | – | – | ++ | +++ | ++ | – |
| **Western immunoblot** | – | – | ++ | +++ | ++ | – |
| **Rapid tests** | – | – | +++ | + | +++ | – |

Key: +++ = recommended for this purpose; ++ recommended but has limitations;   
+ = suitable in very limited circumstances; – = not appropriate for this purpose.

IHC = immunohistochemistry.

A disease-specific partially protease-resistant, misfolded isoform (PrPSc) of a membrane protein PrPC, has a critical importance in the pathogenesis of TSE. According to the prion hypothesis, PrPSc is the principal or sole component of the infectious agent, and confirmation of the diagnosis is reached by the application of immunohistochemical (IHC) or immunochemical detection of PrPSc in brain tissue. By definition, specific demonstration of infectivity would rely on experimental transmission, but ethical considerations and the long incubation periods associated with TSEs mean that the criterion of transmissibility is not used for routine diagnosis. However, biological characterisation on transmission is an important experimental component of the definition of any emerging new phenotypic variants of scrapie and for discriminatory approaches to distinguish cases of scrapie from BSE in sheep or goats.

~~The laboratory diagnosis of classical scrapie relies primarily on the immunodetection of PrP~~~~Sc~~~~, although more traditional histopathology methods can still be used to detect vacuolar lesions in the CNS (Gavier-Widen~~ *~~et al~~*~~., 2005) Histopathological examination, historically based on examination of a single section of medulla oblongata taken at the level of the obex,~~ The medulla oblongata at the level of the obex (the earliest consistent neuroanatomical site for morphological vacuolar changes [Wood *et al*., 1997]) is the most consistent and appropriate diagnostic level of CNS for classical scrapie, using either vacuolation or immunodetection of PrPSc methods. In atypical scrapie, the medulla is affected minimally, while the cerebellum, thalamus and basal ganglia are affected more consistently and overtly (Benestad *et al*., 2008; Moore *et al*., 2008). Therefore, taking practical and logistical sampling considerations into account, the medulla and cerebellum should both be sampled through the foramen magnum and examined to enable the robust diagnosis and classification of classical and atypical scrapie cases.

Although histopathology can still ~~valid~~ be used to detect vacuolar lesions in the CNS (Gavier-Widen *et al*., 2005) at the level of the obex for the confirmation of classical scrapie, ~~but~~ it will not detect atypical scrapie (Moore *et al.,* 2008). However, PrPSc detection using IHC examination or immunodetection techniques, performed on the medulla oblongata, have increased diagnostic sensitivity, and the active surveillance of large populations is now undertaken using rapid PrPSc detection tests (see below). Detectable PrPSc precedes vacuolation and clinical signs, making the immuno-based tests a more sensitive option. ~~While~~ Clinically suspect cases of scrapie ~~should~~ could, where suitable samples are available, continue to be investigated initially by histopathological examination for morphological changes~~, diagnostic criteria must now include the demonstration of PrP~~~~Sc~~ ~~in the CNS. The medulla remains the most consistent and appropriate diagnostic level of the CNS for classical scrapie, however the accumulation pattern of PrP~~~~Sc~~ ~~in atypical scrapie is different~~ . However, any morphological diagnosis must be confirmed by the demonstration of PrPSc in the CNS.

~~In atypical scrapie, the medulla shows only minimal change, while much more consistent and overt lesions can usually be identified in the cerebellum, thalamus and basal ganglia. Therefore, taking practical and logistical sampling considerations into account the medulla and cerebellum should both be examined as a minimum for robust diagnosis and classification.~~

Some commercially available rapid methods for the detection of PrPSc, introduced originally for the diagnosis of BSE, are also approved for scrapie diagnosis and others have been specifically developed and approved for use on small ruminant samples. These rapid tests take the form of ~~Western immunoblot or~~ enzyme-linked immunosorbent assay (ELISA)-based methods, and provide preliminary screening from which samples giving positive or inconclusive results are subject to examination by confirmatory IHC or Western immunoblot methods. All these methods have been shown to be able to detect scrapie in the appropriate samples (EFSA, 2005a; 2012). The analytical sensitivity of these kits is kept under review by the European Commission, and links to information on the performance of currently approved tests can be found on the ~~TSE-LAB-NET~~ [European Reference Laboratory (EURL)](http://www.izsto.it/images/stories/EURL_guidance.zip) website[[3]](#footnote-4). A list of those tests that are currently approved for use by the European Commission can be found in Annex X of Regulation (EC) No. 999/2001 as last amended. Failure to observe either characteristic histological changes or to detect PrPSc does not confirm the absence of the disease; agreement between the results of multiple diagnostic approaches provides the best assurance of accuracy. In surveillance for the purpose of obtaining evidence of freedom from scrapie in small ruminant populations, it may be necessary to apply multiple diagnostic criteria and to use at least two laboratory methods (histopathological and IHC, or immunoblot~~ting~~) on accurately sampled CNS tissue (minimum medulla and cerebellum) to maintain a high degree of confidence in negative results.

Passive surveillance of classical scrapie, comprising the examination of CNS material from clinically suspect cases, has, in recent years, been complemented in many countries by active surveillance, targeting healthy adult culls and fallen stock (diseased or dead animals, also called risk animals) screened at post-mortem using rapid test methods to detect PrPSc. In classical scrapie, the opportunity also exists for screening approaches that do not rely solely on examination of the CNS tissue from dead animals to detect exposed animals, but uses the widespread presence of PrPSc in lymphoreticular tissue in many animals to enable demonstration of infected animals by biopsy of palatine tonsil, nictitating membrane, superficial lymph nodes or, most recently, rectal mucosa lymphoreticular tissue (Gonzalez *et al*., 2006). However it must be noted that not all animals with classical scrapie have detectable lymphoreticular involvement and PrPSc has not yet been detected in the lymphoreticular tissues of cases of sheep or goats with atypical scrapie (Benestad *et al*., 2008). However, the testing of lymphoreticular tissue offers the opportunity to detect some animals infected with classical scrapie at relatively early stages of incubation, before the CNS is positive.

Due to the complex epidemiology of scrapie, the part of the population that should be targeted for sampling, as well as the tissues to be analysed, differs with the different purposes of the testing. Surveillance for prevalence of the disease could limit tissue examination to the CNS of adult sheep and goats for the reasons given above. However, testing to estimate disease prevalence needs to take into account a number of factors, including the stratification of the sheep-farming industry, dose or level of infection within particular flocks, frequency of disease and relative involvement of the LRS in different genotypes, and the effect of genotype/agent strain combination on incubation period.

The need to distinguish between cases of scrapie and possible BSE in sheep and goats has required the development of diagnostic methods with the potential to discriminate between the agents causing these infections. The conformation of disease-specific PrP produced in BSE-infected sheep is different from that of disease-specific PrP found in natural sheep scrapie. These conformational differences may be detected by immunoblot~~ting~~ or IHC techniques using epitope-specific antibodies (summarised in EFSA [2005b]). Within the European Union, the strategy for this distinction comprises examination of source CNS material after initial detection through active or passive surveillance (initial screening) in a primary, secondary and tertiary phase procedure involving a Western immunoblot method capable of such discrimination. This is followed by peer review and further investigation by biochemical and IHC methods of any cases in which primary discrimination was equivocal and, finally, if classification still cannot exclude BSE, mouse transmission to a standardised panel of transgenic mice as described in the ~~EURL Discriminatory Testing Handbook, available on TSE-LAB-NET~~ [EURL Discriminatory Testing Handbook](http://www.izsto.it/images/stories/EURL_guidance.zip). Interpretation of the *in-vitro* methods (Western immunoblot or ELISA) is reliant on differences between BSE and scrapie in the N-terminal cleavage site for Proteinase-K digestion of PrPSc. The *in-situ* IHC approach relies on distribution and epitope-specific labelling patterns of PrPSc in brain and lymphoreticular tissues. Newer *in-vitro* methods, such as quaking-induced conversion (QuIC) (Orru *et al.,* 2012), and protein misfolding cyclic amplification (PMCA) (Castilla *et al.,* 2006) are increasingly being used to increase diagnostic sensitivity, although none have been formally approved for statutory purposes at present. These methods use normal PrP as a substrate, and multiple rounds of protein aggregation to achieve amplification of even very small amounts of PrPSc, PMCA in particular also demonstrates some potential for agent strain discrimination (Gough *et al.,* 2014).

Quality control (QC), quality assurance (QA) and appropriate positive and negative control samples are essential parts of testing procedures and advice and control materials can be requested from the OIE Reference Laboratories.

1. Detection of the agent

1.1. Specimen selection and preparation

Concerns regarding BSE in small ruminant populations and the recognition of atypical scrapie have influenced the strategies for sampling and diagnosis. Although comprehensive sampling and multiple testing methods would provide the most robust contingencies for these and possible future uncertainties in the diagnosis of prion diseases of small ruminants, operational factors also determine what is practical and economical. The relative implementation of passive and active surveillance programmes, and the diagnostic methods applied, further influence sampling strategy. Selection and recommendation of methods is therefore under constant review.

For routine diagnosis, the sampled CNS material is either stored fresh or frozen for subsequent biochemical tests or is fixed for histological preparations. Where programmes are in place to identify possible infections with BSE in small ruminant populations, all sampling should be conducted aseptically, using new sterile disposable instruments, or instruments sterilised under conditions specified for the decontamination of prions (see Chapter 3.4.5 *Bovine spongiform encephalopathy*). Cross contamination at necropsy/sampling should be avoided. Thus, in the following procedures where fresh tissue is sampled for biochemical methods, an aliquot should be reserved for transmission studies. Although in many instances disease can be confirmed on autolysed or suboptimally preserved material, such samples can provide only limited evidence of the absence of scrapie.

1.1.1. Suspect clinical cases

Sheep in which clinical classical or atypical scrapie is suspected (detected by passive surveillance) should be killed by intravenous injection of barbiturate and the whole brain removed by standard necropsy procedures as soon after death as possible. Whole brain removal is advisable to allow pathological examination for differentiation among possible different manifestations of prion disease and the differential diagnosis of non-prion associated brain disorders. Methods of sampling the brain tissue for application of PrP-detection techniques requiring fresh tissue and for histological techniques are based on knowledge of the diagnostic sensitivities of each of the tests for different brain areas and the compromise that precisely the same area cannot be used for both fresh/frozen and fixed tissue approaches. The following protocol is recommended but may be subject to modification to satisfy any particular portfolio of tests. Further information can be obtained from OIE Reference Laboratories (consult the OIE Web site for the most up-to-date list).

Initially, a coronal block of medulla oblongata inclusive of the obex (see chapter 3.4.5, Figure 1) is taken for fixation into at least 10 times its volume of 10% formol saline and held for 3–5 days prior to processing for histopathological and IHC examinations. Care should be taken to ensure that this sample is not frozen. For the detection of PrPSc, fresh tissue samples are taken for immediate testing or stored frozen (–20°C or below) prior to extraction of protein. Specimens should, if possible, provide 5 g of tissue. This should be taken initially from the caudal medulla and, if necessary supplemented with brainstem immediately rostral to the medulla – obex sample. Subsampling of this tissue to accommodate multiple biochemical methods can be achieved by hemisecting in the median plane or by transverse sectioning. Possible variation in sampling for rapid test requirements at the level of the obex is dealt with below in the section on sampling for rapid tests. ~~Where the whole brain is available additional fresh specimens are advocated to minimise false-negative diagnoses, taking into account the possibility that there may be strain-specific targeting of other parts of the brain. For example, in atypical scrapie, cerebellum, thalamus and basal ganglia regions provide the optimal sites for testing, not the medulla (Benestad~~ *~~et al~~*~~., 2008; Moore~~ *~~et al~~*~~., 2008).~~ For optimal detection of atypical scrapie, the cerebellum should also be sampled; part of it should be kept fresh/frozen or fixed as described above. Medulla and cerebellar samples are processed identically.

~~The~~ Where the whole brain is available, after the initial sampling of the medulla and the cerebellum, the remaining brain ~~tissue is~~ should be hemisectioned. One half should be kept fresh/frozen whilst the other half should be fixed in ~~approximately~~ 10 times its volume of 10% formol saline for at least ~~1 week and then cut transversely~~ 7–10 days. This would allow for testing additional brain areas using various methods, including bioassays in rodents, to ~~obtain blocks for histological processing to paraffin wax. The initial sampling of the single block~~ characterise fully the TSE phenotype of ~~the medulla may well be sufficient for IHC and the morphological diagnosis (see chapter 3.4.5, Fig. 1).~~ challenging cases.

Requirements for pathological characterisation or differential diagnosis from other CNS pathological conditions can be fulfilled by taking additional ~~areas of the brain stem and, as necessary, representative blocks~~ sections of all major brain regions~~. Sections 5 µm in thickness, are stained with haematoxylin and eosin and examined initially for the morphological changes and, as required, for IHC detection of PrP~~~~Sc~~~~, as outlined below~~ from the fixed hemisected brain for histological or IHC examination.

1.1.2. Sampling for active surveillance using rapid tests

For the application of rapid tests, methods for removal of the brainstem via the foramen magnum using proprietary spoon-shaped instruments, similar to those employed in cattle for sampling for BSE diagnosis (see chapter 3.4.5, Figure 2) have been devised for sheep. Although not ideal, the approach can also be used for clinical suspect cases. The minimum specimen tissue required is the brainstem at the level of the obex. To detect atypical scrapie the cerebellum should also be sampled with a spoon via the foramen magnum following removal of the brainstem. The brainstem portion is either hemisectioned in the median plane to provide half (fresh/frozen) for a rapid test and half (fixed) for histopathology. Alternatively a complete coronal slice inclusive of the obex is fixed and a similar adjacent caudal medulla slice taken for the rapid test. The complete coronal slice has been recommended in the past to establish the symmetry of morphological changes, but with the use of rapid molecular techniques there is competition between tests for the optimal diagnostic sites at the obex. Some rapid test kits use a core sampling approach to obtain an appropriate mass of material from the obex region. While hemisectioning of the obex region of the brainstem will result in loss of the ability to assess vacuolar lesion symmetry, the greater specificity provided by IHC to detect PrPSc offsets this disadvantage. However if this, or a core sampling approach, is adopted, it is critical to ensure that the contralateral target site is not compromised. The dorsal nucleus of the vagus nerve (the optimal target area for cases of classical scrapie) is a narrow column that lies close to the midline (see chapter 3.4.5, Figure 3). The options are also dependent on the specific sampling instruments provided by the test kit manufacturer.

For all sampling methods it is vital that operators are trained and that the training includes instruction in the gross and cross-sectional neuroanatomy of the brainstem and the precise location of the target areas for disease-specific PrPSc accumulation.

For differentiation of classical and atypical cases, portions of cerebellum are required fixed and fresh/frozen.

1.2. Histological examination

Morphological changes in the CNS are those of a spongiform encephalopathy comprising principally vacuolation of neuronal cell bodies and the surrounding neuropil, accompanied by a variable and usually less conspicuous gliosis (particularly an astrocytic reaction). Typically, the lesions have a bilaterally symmetrical distribution. There is considerable variation in the distribution pattern of vacuolation and other changes. In classical scrapie lesions are usually most apparent in the brainstem and frequently affect the dorsal nucleus of the vagus nerve. Care must be taken if interpreting histopathology alone, as some incidental vacuolation of neurons may also be present in the brains of apparently healthy sheep, albeit at a low frequency (Hornlimann, 2006). There is no direct correlation between the severity of clinical signs and pathological changes. A clinical diagnosis of suspected scrapie cannot be refuted by a failure to find significant vacuolar changes in the brain, and the examination should be supported by tests to detect the accumulation of disease-specific forms of PrP. This is particularly relevant for atypical scrapie, in which there is no vacuolation in the brainstem. In these cases, vacuolation, if it occurs at all, is generally restricted to the molecular layer of the cerebellar cortex, the cerebral cortex and the basal ~~ganglion~~ ganglia.

Despite this variability the histological examination of sections of medulla oblongata at the obex may be sufficient, in most cases, to confirm a diagnosis of clinically suspect classical scrapie (Gavier-Widen *et al*., 2005; Wood *et al*., 1997). The absence of lesions can be established with greatest confidence by examining a number of areas representative of the whole brain.

Although histological examination should not be used as a primary screening or confirmatory test in scrapie surveillance programmes, it can be used to identify scrapie cases by examining haematoxylin and eosin sections that may be generated during other surveillance schemes. Histological examination is still a valuable research tool particularly for recording distribution and intensity of vacuolar lesions in the CNS and for reaching a differential diagnosis in case of a scrapie negative result.

1.3. Detection of disease-specific forms of PrP

Methods for the demonstration of accumulation of disease-specific forms of PrP in specified target areas now provide the principal approach to the diagnosis of both classical and atypical scrapie (Gavier-Widen *et al*., 2005). In suspect clinical cases ~~the combined~~ use of ~~IHC and~~ Western immunoblot~~ting~~, IHC or, wherever possible, both is advocated to confirm the diagnosis. IHC on tissue sections to demonstrate accumulation of PrPSc should be carried out in parallel with routine histology in suspected cases. Combined use of IHC and Western ~~immunoblotting~~ blot is also recommended to provide additional information, particularly where histological lesions are mild in severity and considered equivocal. In active surveillance programmes, the primary diagnosis will usually be accomplished using rapid test methods and, in the case of positive or inconclusive results, confirmatory methods (Western immunoblot, IHC or, ideally, both) should also be applied. A wide range of antisera and monoclonal antibodies for PrP detection by immunochemical methods are now in use and some are commercially available. Advice on test methods and reagents is available from the OIE Reference Laboratories for scrapie~~, and further information is available on their web sites (see chapter 3.4.5)~~ (consult the OIE Web site[[4]](#footnote-5) for the most up-to-date list).

1.3.1. Immunohistochemical methods

Disease-specific accumulation of PrPSc in scrapie-affected brain is demonstrated by IHC on routinely formalin-fixed material by the application of a variety of epitope demasking techniques and the use of appropriate antibodies against PrP. Recognition of morphological disease-specific immunolabelling configurations, their cellular associations and neuroanatomical distribution patterns provide the basis for a confirmatory diagnosis in classical (Ryder *et al*., 2001) and in atypical (Benestad *et al*., 2008) scrapie. ~~As an example, the method used at the European Union Reference Laboratory for TSE, and a list of antibodies proven to be of use for IHC, is provided in the following link~~ [~~http://www.tse-lab-net.eu/documents/tse-oie-rl-prp.pdf~~](http://www.tse-lab-net.eu/documents/tse-oie-rl-prp.pdf)~~.~~ A protocol and a list of antibodies proven to be of use for IHC can be accessed at the [UK OIE Reference Laboratory](http://www.tse-lab-net.eu/documents/tse-oie-rl-prp.pdf) website[[5]](#footnote-6). In recognition of the distribution of generic skills in national reference laboratories, and the power of the IHC approach, variation in methodology is possible from laboratory to laboratory, subject to appropriate proficiency testing and quality assurance.

If histopathological examination and IHC results cannot be achieved, e.g. owing to the poor state of the sample, (i.e. severely autolysed cases), then Western immunoblot~~ting~~ and the rapid test methods are the remaining test options available. Similarly, these methods can also be applied in circumstances where, sometimes in error at necropsy*,* CNS material intended for fixation and histological examination has been frozen. IHC methods can still be applied to ~~such~~ previously frozen samples if they are subsequently fixed, but the ability to identify anatomical sites may be compromised, meaning that any ‘negative’ result must be qualified. With modification, the method for Western immunoblot detection may also be applied successfully to formalin-fixed tissue (Kunkle *et al*., 2008).

1.3.2. Western immunoblot methods

All Western immunoblot~~ting~~ techniques rely on detergent extraction followed by treatment with proteinase K enzyme to digest any normal host protein (PrPc). This leaves only PrPres (the truncated, partially protease-resistant form of the abnormal prion protein [PrPSc]) to be bound by a specific antibody, which provides a detection signal in positive brain samples. A diagnosis based on the detection of PrPres by Western immunoblot~~ting~~ for classical scrapie cases requires that immunolabelled bands corresponding to proteins within a range of molecular mass from 17 kDa (unglycosylated PrPres) to 27 kD (diglycosylated PrPres) be present in the proteinase-K-treated scrapie sample lanes only, and that control sample lanes provide appropriate comparisons. Several sensitive Western immunoblot~~ting~~ methods for the detection of ovine classical scrapie PrPres have been published (Arsac *et al*., 2007; Langeveld *et al.,* 2014; Stack, 2004; Stack *et al.,* 2006).

For atypical or Nor98 scrapie cases, multiple bands are visualised by Western immunoblot~~ting~~ ranging from approximately 11 to 31 kD. As atypical scrapie PrPSc is less resistant to proteinase K digestion than classical scrapie PrPSc, the techniques optimised to detect atypical scrapie employ a reduced concentration of this enzyme in the procedure (Arsac *et al.,* 2007; Benestad *et al*., 2008).

The original technique used for diagnosis of BSE, which has been referred to as ‘the OIE Western immunoblot~~ting~~ technique’ (Stack *et al.,* 2006) relies on detergent extraction of large amounts of fresh brain material (nominally 2–4 g) followed by ultracentrifugation to concentrate the PrP and finally the proteinase K treatment is applied. This technique can also be used to detect classical and atypical scrapie samples.

Detailed protocols for Western ~~immunoblotting can be found on TSE-LAB-NET~~ immunoblot are available from OIE Reference Laboratories for scrapie (consult the OIE Web site for the most up-to-date list).

1.3.3. Rapid test methods

Rapid immunodiagnostic tests for the detection of PrPSc in small ruminant brain tissue have been developed and have been evaluated for diagnostic use (EFSA, 2005a; 2012), and these are all commercially available. Reference should be made to instructions provided by commercial manufacturers, which will have been subject to approval before use, and subsequent quality assurance. Deviation from test methods provided by commercial manufacturers is not normally permitted, and not recommended without assessment and documentation (see Validation Recommendation Chapter 2.5.8 *Comparability of assays after changes in a validated test method*).

The rapid tests rely on the optimisation of the reagents used for extraction and digestion and specific antibodies for detection. The tests require fresh brain tissue, which to maximise diagnostic sensitivity for classical scrapie, should be brainstem taken at the obex or just caudal to the obex. To ensure maximum diagnostic sensitivity for atypical scrapie, cerebellum should also be tested. Most rapid tests use less than 0.5 g of material and many sampling tools are designed to sub-sample precise amounts. However, to allow for possible additional testing at least 1 g of initial sample is advised. If enough tissue is available, some laboratories use the Western immunoblot~~ting~~ technique (see Section B.1.3.2 above) to confirm any weak-positive samples that are initially detected using a rapid test. The increased amount or concentration of PrPres extracted by ultracentrifugation from the larger aliquot of brain tissue can give improved sensitivity.

Prospects for more sensitive diagnostic tests for scrapie and other TSEs are mainly directed at present on the refinement of existing methods and the development of new approaches to the detection of disease-specific forms of PrP. Achievement of the consistent performance of rapid test methods for the primary diagnostic approach is paramount~~, particularly with regard to the capacity of tests to recognise both classical and atypical scrapie phenotypes, as well as BSE in small ruminants. Overall diagnostic sensitivity is strongly influenced by the accuracy of sampling.~~ Overall diagnostic sensitivity is strongly influenced by the accuracy of sampling. In addition, some ELISA-based rapid tests appear to have limited sensitivity when applied to goat samples (Corbiere *et al.,* 2013; Simmons *et al.,* 2020). These tests have not been validated for this species but it has been assumed that they are suitable for detecting scrapie in caprine samples because they have been used successfully for this purpose in ovine samples. There is evidence that goat PrP polymorphisms may also affect the performance of other immunoassays (Western immunoblot, IHC) in an antibody-dependent manner (Madsen-Bouterse *et al.,* 2015; Mazza *et al.,* 2012).

1.4. Other diagnostic tests

As for BSE of cattle (see chapter 3.4.5) tests that can be applied effectively to the live animal to detect scrapie cases in the early stage of incubation remain elusive, despite several avenues of research. The pursuit of non-prion protein biomarkers, including possibly through metabolomic or proteomic approaches, may offer prospects but there are constraints including accessibility of tissue to be tested and specificity of the test method. Two methods using *in-vitro* protein amplification have been developed: protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC). They are proving to be very sensitive for the detection of some prion diseases (Castilla *et al.,* 2006; Orru *et al.,* 2012), but have not yet been formally evaluated for application within statutory surveillance systems, although some have been successfully piloted for surveillance applications in humans (Lacroux *et al.,* 2014; Orru *et al.*, 2014).

2. Serological tests

An antibody response to the scrapie agent has not been detected and so serological tests are not feasible.

3. Genetic screening for resistance

Scrapie control and elimination strategies based on genetic selection for resistance to classical scrapie in sheep have been deployed successfully in some countries. Selection is made on determination of the common polymorphisms of the sheep *PrP* gene. As an aid to the control of classical scrapie: breeding stock, particularly rams, of appropriate *PrP* genotype can be selected to produce progeny with reduced risk of developing disease (recently reviewed in EFSA 2014). Such genotyping services are available on a commercial basis in North America and in several countries in Europe. The test is performed using DNA extracted from white blood cells obtained from ethylene diamine tetra-acetic acid (EDTA)-treated blood samples. (Other tissue such as skin [e.g. ear punches] can also be used, as can other tissues such as brain, for screening cull population samples.) Selection of breeding stock can be based on the most scrapie-resistant animals, i.e. animals of genotypes which encode alanine on both alleles at codon 136, arginine on both alleles at codon 154 and arginine on both alleles at codon 171 (so called ARR/ARR animals), thereby reducing the incidence of classical scrapie in individual flocks. However, these animals are not always common in flocks, and in some breeds the genotype is actually absent.

A breeding programme selecting ARR/ARR sheep will not however ensure resistance to atypical scrapie. Decisions on the appropriateness of such programmes must take into account a thorough evaluation of the current national/regional/local scrapie situation, the availability of replacement resistant sheep, the sheep importation policy, availability of testing facilities and the desirability and support of the sheep industry; especially the willingness of sheep breeders to commit themselves to the programme for a long period of time.

Unlike in sheep, in goats none of the PrP polymorphisms that are associated with genetic resistance to scrapie are distributed universally in relative abundance. Consequently application of scrapie control and elimination programmes in this species has been successful only in limited cases were appropriate polymorphisms have been identified to allow selection for genetic resistance to scrapie in goats (EFSA, 2017; Georgiadou *et al.* 2017).

C. REQUIREMENTS FOR VACCINES ~~AND DIAGNOSTIC BIOLOGICALS~~

There are no ~~biological products~~ vaccines available.

REFERENCES

Arsac J.N., Andreoletti O., Bilheude J.M., Lacroux C. Benestad S.L. & Baron T. (2007). Similar biochemical signatures and prion protein genotypes in atypical scrapie and Nor98 cases, France and Norway. *Emerg. Infect. Dis*., **13**, 58–65.

Benestad S.L., Arsac J-N., Goldmann W. & Nöremark M. (2008). Atypical/Nor98 scrapie: properties of the agent, genetics and epidemiology. *Vet. Res.,* **39**, 19.

Cassard H., Torres J.M., Lacroux C., Douet J.Y., Benestad S.L., Lantier F., Lugan S., Lantier I., Costes P., Aron N., Reine F., Herzog L., Espinosa J.C., Beringue V. & Andréoletti O. (2014). Evidence for zoonotic potential of ovine scrapie prions. *Nat. Commun*., **5**, 5821.

Castilla J., Saa P., Morales R., Abid K., Maundrell K. & Soto C. (2006). Protein misfolding cyclic amplification for diagnosis and prion propagation studies. *Methods Enzymol.*, **412**, 3–21.

Comoy E.E., Mikol J., Luccantoni-Freire S., Correia E., Lescoutra-Etchegaray N., Durand V., Dehen C., Andreoletti O., Casalone C., Richt J.A., Greenlee J.J., Baron T., Benestad S.L., Brown P. & Deslys J.P. (2015). Transmission of scrapie prions to primate after an extended silent incubation period. *Sci. Rep.*, **5**, 11573. doi: 10.1038/srep11573.

Corbiere F., Chauvineau-Perrin C., Lacroux C, Lugan S., Costes P., Thomas M., Brémaud I., Chartier C., Barillet F., Schelcher F. & Andréoletti O. (2013). The Limits of Test-Based Scrapie Eradication Programs in Goats. *PLoS One,* **8**(1): e54911. doi:10.1371/journal.pone.0054911.

Dexter G., Tongue S., Heasman L., Bellworthy S., Davis A., Moore S.J., Simmons M.M., Sayers R., Simmons H.A. & Matthews D. (2009). The evaluation of exposure risks for natural transmission of scrapie within an infected flock. *BMC Vet. Res*., **5**, 38.

Epstein V., Pointing S. & Halfacre S. (2005). Atypical scrapie in the Falkland Islands. *Vet. Rec.,* **157**, 667–668.

European Food Safety Authority (EFSA) (2005a). Evaluation of rapid post-mortem TSE tests intended for small ruminants. *EFSA Scientific Report*, **49**, 1–16.

European Food Safety Authority (EFSA) (2005b). Opinion on classification of atypical transmissible spongiform encephalopathy (TSE) cases in small ruminants. *EFSA J.,* **276**, 1–30.

European Food Safety Authority (EFSA) (2012). Scientific Opinion on the evaluation of new TSE rapid tests submitted in the framework of the Commission Call for expression of interest ~~2007/S204-247339~~. *EFSA J.,* **10**, 2660

European Food Safety Authority (EFSA) (2014). Scientific Opinion on the scrapie situation in the EU after 10 years of monitoring and control in sheep and goats. *EFSA J.,* **12**, 378~~1~~.

European Food Safety Authority (EFSA) (2017). Scientific opinion on genetic resistance to transmissible spongiform encephalopathies (TSE) in goats. *EFSA J.*, **15**, 4962.

Gavier-Widen D., Stack M.J., Baron T., Balachandran A. & Simmons M. (2005). Diagnosis of transmissible spongiform encephalopathies in animals: a review. *J. Vet. Diagn. Invest.,* **17**, 509–527.

Georgiadou S., Ortiz-Pelaez A., Simmons M.M., Windl O., Dawson M., Neocleous P. & Papasavva-Stylianou P. (2017). Goats with aspartic acid or serine at codon 146 of the PRNP gene remain scrapie-negative after lifetime exposure in affected herds in Cyprus. *Epidemiol. Infect.,* **145**, 326–328. doi:10.1017/S0950268816002272.

Gonzalez L., Dagleish M.P., Bellworthy S., Sisó S., Stack M.J., Chaplin M.J., Davis L.A., Hawkins S.A.C., Hughes J. & Jeffrey M. (2006). Postmortem diagnosis of preclinical and clinical scrapie in sheep by the detection of disease-associated PrP in their rectal mucosa. *Vet. Rec.*, **158**, 325–331.

Gough K.C., Baker C.A., Simmons H.A., Hawkins S.A. & Maddison B.C. (2015). Circulation of prions within dust on a scrapie affected farm. *Vet. Res*., **46**, 40.

Gough K.C., Bishop K. & Maddison B.C. (2014). Highly sensitive detection of small ruminant bovine spongiform encephalopathy within transmissible spongiform encephalopathy mixes by serial protein misfolding cyclic amplification. *J. Clin. Microbiol*., **52**, 3863–3868.

Hawkins S.A., Simmons H.A., Gough K.C. & Maddison B.C. (2015). Persistence of ovine scrapie infectivity in a farm environment following cleaning and decontamination. *Vet. Rec.,* **176**, 99.

Hornlimann B. (2006). Prions in Humans and Animals, Hörnlimann B., Riesner, D. & Kretzschmar H., eds. de Gruyter, Berlin, Germany.

Kittelberger R., Chaplin M.J., Simmons M.M., Ramirez-Villaescusa A., McIntyre L., MacDiarmid S.C., Hannah M.J., Jenner J., Bueno R., Bayliss D., Black H., Pigott C.J. & O’Keefe J.S. (2010). Atypical scrapie/Nor98 in a sheep from New Zealand. *J. Vet. Diagn. Invest*., **22**, 863–875.

Konold T., Moore S.J., Bellworthy S.J., Terry L.A., Thorne L., Ramsay A., Salguero F.J., Simmons M.M. & Simmons H.A. (2013). Evidence of effective scrapie transmission via colostrum and milk in sheep. *BMC Vet. Res.,* **9**, 99.

Konold T. & Phelan L. (2014). Clinical examination protocol to detect atypical and classical scrapie in sheep*. J. Vis. Exp.*, **83**:e51101. doi:10.3791/51101.

Kunkle R.A., Nicholson E.M., Lebepe-Mazur S., Orcutt D.L., Srinivas M.L., Greenlee J.J., Alt D.P. & Hamir A.N. (2008). Western blot detection of PrP Sc in archived paraffin-embedded brainstem from scrapie-affected sheep. *J. Vet. Diagn. Invest.*, **20**, 522–526.

Lacroux C., Comoy E., Moudjou M., Perret-Liaudet A., Lugan S., Litaise C., Simmons H., Jas-Duval C., Lantier I., Béringue V., Groschup M., Fichet G., Costes P., Streichenberger N., Lantier F., Deslys J.P., Vilette D. & Andréoletti O. (2014). Preclinical detection of variant CJD and BSE prions in blood. *PLoS Pathog.,* **10**:e1004202.

Langeveld J.P., Jacobs J.G., Erkens J.H., Baron T., Andréoletti O., Yokoyama T., van Keulen L.J., van Zijderveld F.G., Davidse A., Hope J., Tang Y. & Bossers A. (2014). Sheep prions with molecular properties intermediate between classical scrapie, BSE and CH1641-scrapie. *Prion*, **8**, 296–305. doi: 10.4161/19336896.2014.983396.

Loiacono C.M., Thomsen B.V., Hall S.M., Kiupel M., Sutton D., O’Rourke K., Barr B., Anthenill L. & Keane D. (2009). Nor98 scrapie identified in the United States. *J. Vet. Diag. Invest*., **21**, 454–463.

Madsen-Bouterse S.A., Schneider D.A., Dassanayake R.P., Truscott T.C., Zhuang D., Kumpula-McWhirter N., & O’Rourke K.I. (2015) PRNP variants in goats reduce sensitivity of detection of PrPSc by immunoassay. *J. Vet. Diag. Invest.*, **27**, 332–343.

Mazza M., Guglielmetti C., Pagano M., Sciuto S., Ingravalle F., M., Caramelli M. & Acutis P.L. (2012). Lysine at position 222 of the goat prion protein inhibits the binding of monoclonal antibody F99/97.6.1. *J. Vet. Diag. Invest.*, **24**, 971–975.

Mazza M, Iulini B., Vaccari G., Acutis P.L, Martucci F., Esposito E., Peletto S., Barocci S., Chiappini B., Corona C., Barbieri I., Caramelli M., Agrimi U., Casalone C. & Nonno R. (2010). Co-existence of classical scrapie and Nor98 in a sheep from an Italian outbreak. *Res. Vet. Sci.*, **88**, 478–485.

Moore S.J., Simmons M.M., Chaplin M.J. & Spiropoulos J. (2008). Neuroanatomical distribution of abnormal prion protein in naturally occurring atypical scrapie cases in Great Britain. *Acta Neuropathologica,* **116**, 547–559.

Orru C.D., Bongianni M., Tonoli G., Ferrari S., Hughson A.G., Groveman B.R., Fiorini M., Pocchiari M., Monaco S., Caughey B. & Zanusso G. (2014). A test for Creutzfeldt-Jakob disease using nasal brushings. *N. Engl. J. Med*., **371**, 519–529.

Orru C.D., Wilham J.M., Vascellari S., Hughson A.G. & Caughey B. (2012). New generation QuIC assays for prion seeding activity. *Prion*, **6**, 147–152. doi: 10.4161/pri.19430.

Ryder S.J., Spencer Y.I., Bellerby P.J. & March S.A. (2001). Immunohistochemical detection of PrP in the medulla oblongata of sheep: the spectrum of staining in normal and scrapie-affected sheep. *Vet. Rec*., **148**, 7–13.

Simmons M.M., Moore S.J., Konold T., Thurston L., Terry L.A., Thorne L., Lockey R., Vickery C., Hawkins S.A.C., Chaplin M.J. & Spiropoulos J. (2011). Experimental oral transmission of atypical scrapie to sheep. *Emerg. Infect. Dis*., **17**, 848–854.

Simmons M.M., Thorne L., Ortiz-Pelaez A., Spiropoulos J., Georgiadou S., Papasavva-Stylianou P., Andreoletti O., Hawkins S.A.C., Meloni D. & Cassar C. (2020). Transmissible spongiform encephalopathy in goats: is PrP rapid test sensitivity affected by genotype? *J. Vet. Diagn. Invest.,* **32**, 87–93. doi: 10.1177/1040638719896327.

SpiropoulosJ., Hawkins S.A., Simmons M.M. & Bellworthy S.J. (2014). [Evidence of *in utero* transmission of classical scrapie in sheep.](http://www.ncbi.nlm.nih.gov/pubmed/24453368) *J. Virol*., **88**, 4591–4594. doi: 10.1128/JVI.03264-13. Epub 2014 Jan 22.

Stack M.J. (2004). Western Immunoblotting Techniques for the Study of Transmissible Spongiform Encephalopathies. *In*: Techniques in Prion Research, Lehmann S. & Grassi J., eds. Birkhäuser Verlag, Switzerland, 97–116.

Stack M., Jeffrey M., Gubbins S., Grimmer S., Gonzalez L., Martin S., Chaplin M., Webb P., Simmons M., Spencer Y., Bellerby P., Hope J., Wilesmith J. & Matthews D. (2006). Monitoring for bovine spongiform encephalopathy in sheep in Great Britain, 1998–2004. *J. Gen. Virol*., **87**, 2099–2107.

Wood J.L.N., McGill I.S., Done S.H. & Bradley R. (1997). Neuropathology of scrapie: a study of the distribution patterns of brain lesions in 222 cases of natural scrapie in sheep, 1982–1991. *Vet. Rec.,* **140**, 167–174.

\*  
\* \*

**NB:** There are OIE Reference Laboratories for Scrapie  
(see OIE Web site for the most up-to-date list:   
<https://www.oie.int/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).   
Please contact the OIE Reference Laboratories for any further information on   
diagnostic tests and reagents for scrapie

**NB:** First adopted in 1989; Most recent updates adopted in 2016.

1. <http://www.oie.int/en/animal-health-in-the-world/the-world-animal-health-information-system/the-world-animal-health-information-system/> [↑](#footnote-ref-2)
2. https://science.vla.gov.uk/tseglobalnet/documents/clinical-signs-tse-sheep-video.pdf [↑](#footnote-ref-3)
3. http://www.izsto.it/index.php/centri-di-eccellenza/174-centri-di-eccellenza/2397-laboratorio-di-riferimento-europeo-per-le-encefalopatie-spongiformi-trasmissibili [↑](#footnote-ref-4)
4. <https://www.oie.int/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3> [↑](#footnote-ref-5)
5. <https://science.vla.gov.uk/tseglobalnet/confirmatory-diagnosis.html> [↑](#footnote-ref-6)